Dopamine Agonists: From the 1970s to Today
Neuroendocrinology, 2019 The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting ...
R. Auriemma +4 more
semanticscholar +1 more source
Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels [PDF]
, 2013 Objective Impulse control disorders are commonly associated with dopaminergic therapy in Parkinson's disease (PD). PD patients with impulse control disorders demonstrate enhanced dopamine release to conditioned cues and a gambling task on [11C]raclopride
A. Rizos +43 more
core +1 more source
RGS4 regulates partial agonism of the M2 muscarinic receptor-activated K+ currents. [PDF]
, 2014 Partial agonists are used clinically to avoid overstimulation of receptor-mediated signalling, as they produce a submaximal response even at 100% receptor occupancy.
Chen, I-Shan +3 more
core +2 more sources
Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle [PDF]
PeerJ 1:e117, 2013, 2013 Pharmacological challenge imaging has mapped, but rarely quantified, the sensitivity of a biological system to a given drug. We describe a novel method called rapid quantitative pharmacodynamic imaging. This method combines pharmacokinetic-pharmacodynamic modeling, repeated small doses of a challenge drug over a short time scale, and functional imaging
arxiv +1 more source
Acting without being in control: Exploring volition in Parkinson's disease with impulsive compulsive behaviours. [PDF]
, 2017 BACKGROUND: Several aspects of volitional control of action may be relevant in the pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson's disease (PD).
de Boer, L +6 more
core +2 more sources
Dopamine Agonists and Impulse Control Disorders: A Complex Association
Drug Safety, 2017 Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use.
M. Grall-Bronnec +8 more
semanticscholar +1 more source
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. [PDF]
, 2013 RationaleImpaired cognitive abilities are a key characteristic of schizophrenia. Although currently approved pharmacological treatments have demonstrated efficacy for positive symptoms, to date no pharmacological treatments successfully reverse cognitive
Acheson, Dean T +2 more
core +2 more sources
Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
Journal of Investigative Medicine High Impact Case Reports, 2021 Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine.
Lakshmi P. Menon MD, Wedad Rahman MD
doaj +1 more source
Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome:therapeutic perspectives for 5-HT1A agonists [PDF]
, 2014 Rett syndrome is a neurological disorder caused by loss of function of methyl-CpG-binding protein 2 (MeCP2). Reduced function of this ubiquitous transcriptional regulator has a devastating effect on the central nervous system.
Abdala, Ana Paula +2 more
core +2 more sources
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
European Journal of Endocrinology, 2016 OBJECTIVE Clinically nonfunctioning pituitary adenoma (NFPA) remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended.
Y. Greenman +11 more
semanticscholar +1 more source